Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs iShares Self-Driving EV and Tech (IDRV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs iShares Self-Driving EV and Tech — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.01 (market cap $39.89B), while iShares Self-Driving EV and Tech trades at $36.65. The key difference: iShares Self-Driving EV and Tech is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | IDRV | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | Sector/Thematic |
52-Week High | $491.22 | $45.48 |
52-Week Low | $278.09 | $32.13 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
IDRV trades at $36.86 with a slight 0.33% daily gain, but technical indicators signal a bearish trend with 19 sell signals versus 3 buys. The stock faces resistance at $37-$38 while finding support at $35-$36. Recent news highlights strong global EV sales growth, particularly in China and Europe, though U.S. adoption remains slower. Key financial ratios including P/E, P/S, and ROE are currently unavailable for analysis.
The EV sector shows promising growth catalysts from rising fuel prices and expanding global adoption, but IDRV faces technical headwinds and competitive pressures. Investment appeal depends on improved fundamental metrics and sector momentum overcoming current bearish technical positioning. Regulatory developments and Chinese market expansion present both opportunities and risks for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About iShares Self-Driving EV and Tech
IDRV invests in global companies at the forefront of self-driving and electric vehicle innovation. It provides exposure to the full EV value chain, including battery technology and autonomous systems, with top holdings like Albemarle, Rivian, and Tesla.
Read more on IDRV →
